Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Morrato, Elaine H
2012.
An update on lipid profile screening in second-generation antipsychotic users in the USA.
Clinical Lipidology,
Vol. 7,
Issue. 5,
p.
509.
van Gool, Ronald
and
van Meijel, Berno
2012.
Mind the body!.
Nederlands Tijdschrift voor Evidence Based Practice,
Vol. 10,
Issue. 2,
p.
4.
Galletly, Cherrie A
Foley, Debra L
Waterreus, Anna
Watts, Gerald F
Castle, David J
McGrath, John J
Mackinnon, Andrew
and
Morgan, Vera A
2012.
Cardiometabolic risk factors in people with psychotic disorders: The second Australian national survey of psychosis.
Australian & New Zealand Journal of Psychiatry,
Vol. 46,
Issue. 8,
p.
753.
Binford, Sandra Haas
Johnson, Monique D.
Kennedy, Robert S.
and
Leffler, Joy Bartnett
2012.
Clinician Education Improves Lipid Monitoring in Patients Taking Second-Generation Antipsychotic Agents, Nationally and Locally.
Health Outcomes Research in Medicine,
Vol. 3,
Issue. 3,
p.
e121.
Papanastasiou, Evangelos
2012.
Interventions for the metabolic syndrome in schizophrenia: a review.
Therapeutic Advances in Endocrinology and Metabolism,
Vol. 3,
Issue. 5,
p.
141.
De Hert, Marc
Detraux, Johan
van Winkel, Ruud
Yu, Weiping
and
Correll, Christoph U.
2012.
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
Nature Reviews Endocrinology,
Vol. 8,
Issue. 2,
p.
114.
Mitchell, Alex J.
2012.
Psychiatric aspects of chronic physical disease.
Medicine,
Vol. 40,
Issue. 12,
p.
662.
Vancampfort, D.
Probst, M.
Scheewe, T.
Knapen, J.
De Herdt, A.
and
De Hert, M.
2012.
The functional exercise capacity is correlated with global functioning in patients with schizophrenia.
Acta Psychiatrica Scandinavica,
Vol. 125,
Issue. 5,
p.
382.
Mitchell, Alex J
2012.
Understanding disproportionately high cardiometabolic risk in Australians treated for psychosis.
Australian & New Zealand Journal of Psychiatry,
Vol. 46,
Issue. 10,
p.
919.
Mitchell, Alex J.
Delaffon, Vijay
and
Lord, Oliver
2012.
Let's get physical: improving the medical care of people with severe mental illness.
Advances in Psychiatric Treatment,
Vol. 18,
Issue. 3,
p.
216.
Lahti, M.
Tiihonen, J.
Wildgust, H.
Beary, M.
Hodgson, R.
Kajantie, E.
Osmond, C.
Räikkönen, K.
and
Eriksson, J.
2012.
Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia.
Psychological Medicine,
Vol. 42,
Issue. 11,
p.
2275.
Mitchell, A. J.
Vancampfort, D.
De Herdt, A.
Yu, W.
and
De Hert, M.
2013.
Is the Prevalence of Metabolic Syndrome and Metabolic Abnormalities Increased in Early Schizophrenia? A Comparative Meta-Analysis of First Episode, Untreated and Treated Patients.
Schizophrenia Bulletin,
Vol. 39,
Issue. 2,
p.
295.
Butler, Phalyn
Simonson, Caitlin
Goldie, Christa
Kennedy, Amy
and
Goldstone, Lisa W.
2013.
Baseline metabolic monitoring of atypical antipsychotics in an inpatient setting.
Mental Health Clinician,
Vol. 3,
Issue. 3,
p.
122.
Foley, Debra L.
Mackinnon, Andrew
Watts, Gerald F.
Shaw, Jonathan E.
Magliano, Dianna J.
Castle, David J.
McGrath, John J.
Waterreus, Anna
Morgan, Vera A.
Galletly, Cherrie A.
and
Vinciguerra, Manlio
2013.
Cardiometabolic Risk Indicators That Distinguish Adults with Psychosis from the General Population, by Age and Gender.
PLoS ONE,
Vol. 8,
Issue. 12,
p.
e82606.
Lang, Donna J.
Barr, Alasdair M.
and
Procyshyn, Ric M.
2013.
Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness.
Current Cardiovascular Risk Reports,
Vol. 7,
Issue. 4,
p.
283.
Vancampfort, Davy
De Hert, Marc
Sweers, Kim
De Herdt, Amber
Detraux, Johan
and
Probst, Michel
2013.
Diabetes, physical activity participation and exercise capacity in patients with schizophrenia.
Psychiatry and Clinical Neurosciences,
Vol. 67,
Issue. 6,
p.
451.
Guenette, Melanie D.
Hahn, Margaret
Cohn, Tony A.
Teo, Celine
and
Remington, Gary J.
2013.
Atypical antipsychotics and diabetic ketoacidosis: a review.
Psychopharmacology,
Vol. 226,
Issue. 1,
p.
1.
Burghardt, Kyle J.
and
Ellingrod, Vicki L.
2013.
Detection of Metabolic Syndrome in Schizophrenia and Implications for Antipsychotic Therapy.
Molecular Diagnosis & Therapy,
Vol. 17,
Issue. 1,
p.
21.
Owen, Richard R
Drummond, Karen L
Viverito, Kristen M
Marchant, Kathy
Pope, Sandra K
Smith, Jeffrey L
and
Landes, Reid D
2013.
Monitoring and managing metabolic effects of antipsychotics: a cluster randomized trial of an intervention combining evidence-based quality improvement and external facilitation.
Implementation Science,
Vol. 8,
Issue. 1,
Murphy, Andrea Lynn
Gardner, David Martin
Kisely, Steve
Cooke, Charmaine
Kutcher, Stanley Paul
and
Hughes, Jean
2013.
Youth, Caregiver, and Prescriber Experiences of Antipsychotic-Related Weight Gain.
ISRN Obesity,
Vol. 2013,
Issue. ,
p.
1.